Immunology Drug Market – Global Market Size, Strategic Growth Drivers, Risk Assessment Framework, Regulatory Landscape Review, Competitive Intensity Mapping & Long-Term Industry Outlook to 2034
Overview
The Immunology Drug Market size was valued at USD 126.54 Billion in 2025 and the total Immunology Drug revenue is expected to grow at a CAGR of 8.1% from 2026 to 2034, reaching nearly USD 255.07 Billion.
Immunology Drug Market Overview:
They are used to fight infection, prevent or treat immunological disorders. The rise in awareness regarding immunological disease in both developed and developing countries and the growing prevalence of immunological disorders because of environmental changes and changing lifestyles these factors are responsible for propelling the market growth. Some of the key market players are constantly focusing on innovation and upgrading their product portfolio for better treatment outcomes for the patients. This is also estimated to grow further during the forecast period. Over 1.2 Mn people suffer from moderate to severe plaque psoriasis currently around 6% of the patients are being treated with biologics this presents of significant opportunity for the drug manufacturers.
Immunology Drug Market Size, Growth and Share Analysis
To know about the Research Methodology :- Request Free Sample Report
Immunology Drug Market Dynamics:
Increasing various type of environmental factors including exposure to the toxic chemical, stress, dietary component, and infection gives rise to a large patient pool suffering from autoimmune disease. According to research by the National Stem Cell Foundation, nearly 4% of the world's population is getting affected by one or more than 80 different autoimmune diseases. The increasing prevalence of viral infection in shrimp farming has increased the high demands of autoimmune disease and its Diagnostics.
In February 2021, Sandoz Canada introduced adalimumab (HUMIRA) bio similar, Hyrimoz, in Canada. The company confirmed that the drug received approval and provide high efficacy to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, adult Crohn’s disease, and adult uveitis, among others. The rising number of successful clinical trials is driving the demand for biological several companies to invest in Research and Development to develop biosimilar and affordable and effective imitation of the biological drugs hence the Increasing demand for such products.
In September 2020, Lupin launched generic Rheumatoid Arthritis drug, Leflunomide, in the US, this is estimated to derive the market growth during the forecast period. Additionally, these drugs are associated with various adverse effects such as infection, Allergic reaction, Muscle ache Fever and fast irregular pounding, and others. Hence these factors and the reimbursement policies in developing regions hamper the market growth during the forecast period.
Immunology Drug Market Segment Analysis:
The Immunology Drug Market is segmented By Drug Class type and Disease Condition.
Based on the Drug Class Type, The Immunology Drug Market is segmented into Monoclonal antibodies, Fusion proteins, Immunosuppressant, Polyclonal Antibody. The monoclonal Antibody segment is dominated by the Immunology Drug Market with the highest market share of 39.1% in the year 2025. The dominance is attributed to the established clinical efficiency of monoclonal antibodies such as adalimumab, rituximab, and treatment of rare and chronic conditions and autoimmune diseases. In Addition to this higher number of approvals for these drugs. Increase sing adoption of immunosuppressant’s in developing nations because of their higher treatment efficacy contributes to their faster growth rate.
Based on the Disease Condition, The Immunology Drug Market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Inflammatory Bowel Disease, and Prophylaxis of Organ Rejection. The Rheumatoid Arthritis segment dominated the market with the highest CAGR of 3.4% in the year 2025. This segment is also expected to grow with the highest market share of xx% in the year 2020. Increasing prevalence of Rheumatoid Arthritis and rising number of patients, expected to increase the demand for Rheumatoid Arthritis treatment. According to the regional and national database, the global incidence of Rheumatoid Arthritis is around 3 cases per 10,000, whereas the global prevalence is estimated at 1% to 2% of the total population.
Immunology Drug Market Regional Insights:
North America dominated the Immunology Drug Market with the largest market share of 41.3% in 2025. It is also expected to register highest at a CAGR of xx% during the forecast period. The presence of well-established healthcare infrastructure, higher prevalence of chronic conditions and comparatively higher diagnosis and treatment rates among the patient population in the U.s are the factors responsible for the dominance of the region in the global market.
Europe is anticipated to register a significant CAGR during the forecasting period. Rising prevalence of autoimmune conditions and increase drug approval in the region, For example in 2019 estimated 40,000 people in the UK were suffering from Rheumatoid Arthritis and 4 Mn people were suffering from autoimmune disease. The market in the Asia Pacific is expected to grow at the highest CAGR of xx% during the forecasting period.
Asia Pacific region is expected to hold the highest CAGR of around 2.3% during the forecast period. Rising obesity in people and increasing geriatric population especially in developing countries such as China and India are increasing the demand for the Immunology Drug Market. Europe Immunology Drug Market is expected to at steady rate during the forecast period.
The objective of the report is to present a comprehensive analysis of the Immunology Drug Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.
PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The reports also helps in understanding the Immunology Drug Market dynamic, structure by analyzing the market segments and project the Immunology Drug Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Immunology Drug Market make the report investor’s guide.
Immunology Drug Market Recent Development
| Date | Company | Development | Impact |
|---|---|---|---|
| 15 April 2025 | AbbVie Inc. | AbbVie received U.S. FDA approval for RINVOQ (upadacitinib) for the treatment of giant cell arteritis after Phase 3 trials demonstrated a 46.4% sustained remission rate versus 29.0% on placebo. | This approval marks RINVOQ's ninth U.S. label expansion in immunology, strengthening AbbVie's market position in targeted oral autoimmune therapeutics. |
| 18 December 2025 | Amgen Inc. | Amgen secured U.S. FDA approval for UPLIZNA (inebilizumab-cdon) for adult patients with generalized myasthenia gravis. | The regulatory milestone significantly broadens Amgen's targeted B-cell targeted autoimmune portfolio into rare neurological immunology conditions. |
| 15 March 2026 | Johnson & Johnson | Johnson & Johnson announced a major strategic investment exceeding USD 1 billion to construct a new cell therapy manufacturing facility in Montgomery County, Pennsylvania. | The dedicated commercial facility dramatically enhances supply chain scale and production capacity for the company's expanding oncology and immunology pipeline. |
| 12 April 2026 | Johnson & Johnson | Johnson & Johnson achieved U.S. FDA label expansion for STELARA (ustekinumab) to treat pediatric Crohn's disease in patients aged 2 years and older. | The approval expands therapeutic options for early-onset pediatric inflammatory bowel disease while extending the clinical reach of the IL-12/23 inhibitor class. |
| 28 April 2026 | Sanofi and Regeneron Pharmaceuticals | Sanofi and Regeneron obtained U.S. FDA approval for DUPIXENT (dupilumab) in pediatric patients aged 2 to 11 years with chronic spontaneous urticaria. | This decision introduces a targeted biologic option for young pediatric patients with uncontrolled skin inflammation, broadening DUPIXENT's dominant market footprint in type 2 inflammation. |
| 14 May 2026 | Formycon / Teva Pharmaceutical | The U.S. FDA granted regulatory approval for IMMGOLIS and IMMGOLIS INTRI, marking the approval of the first biosimilars to Simponi and Simponi Aria (golimumab). | The approval introduces cost-effective anti-TNF biologic choices for rheumatoid arthritis and psoriatic disease, accelerating biosimilar competition in mature immunology markets. |
Immunology Drug Market Scope: Inquire before buying
| Immunology Drug Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 126.54 Bn. |
| Forecast Period 2026 to 2034 CAGR: | 8.1% | Market Size in 2034: | USD 255.07 Bn. |
| Segments Covered: | by Drug Class Type | Monoclonal Antibody Fusion Proteins Immunosuppressant Polyclonal Antibody |
|
| by Disease Condition | Rheumatoid Arthritis Psoriatic Arthritis Plaque Psoriasis Inflammatory Bowel Disease Prophylaxis of Organ Rejection |
||
| by Distribution Channel |
Hospital Pharmacies Retail Pharmacies Online Pharmacies |
||
Immunology Drug Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Immunology Drug Market, Key Players:
The Immunology Drug refers to the global economic sector involving the research, development, manufacturing, and sale of pharmaceutical products that modify or regulate the human immune system. These therapeutics including monoclonal antibodies, immunosuppressants, and fusion proteins are used to treat autoimmune diseases, chronic inflammatory conditions, allergies, and organ transplant rejections.
| Company Name | Headquarters | Core Competencies |
| Pfizer Inc. | New York, New York, USA | Immunology, inflammation, autoimmune diseases, biologics, specialty medicines |
| F. Hoffmann-La Roche Ltd. | Basel, Switzerland | Immunology, biologics, monoclonal antibodies, precision medicine |
| AbbVie Inc. | North Chicago, Illinois, USA | Immunology biologics, autoimmune disease therapies, inflammatory disorders |
| Bristol Myers Squibb | Princeton, New Jersey, USA | Immunology, oncology, cardiovascular, autoimmune therapies |
| Merck & Co., Inc. | Rahway, New Jersey, USA | Immunology, vaccines, biologics, specialty pharmaceuticals |
| Novartis AG | Basel, Switzerland | Immunology, dermatology, rheumatology, biologics |
| Johnson & Johnson Innovative Medicine | Raritan, New Jersey, USA | Immunology, inflammatory bowel disease, psoriasis, autoimmune disorders |
| Amgen Inc. | Thousand Oaks, California, USA | Immunology, inflammation, biologics, biosimilars |
| UCB SA | Brussels, Belgium | Immunology, autoimmune diseases, neurology, biologics |
| Eli Lilly and Company | Indianapolis, Indiana, USA | Immunology, dermatology, autoimmune disease therapies |
| Sanofi | Paris, France | Immunology, rare diseases, biologics, inflammatory disorders |
| AstraZeneca | Cambridge, England, United Kingdom | Immunology, respiratory diseases, biologics, inflammation |
| Regeneron Pharmaceuticals | Tarrytown, New York, USA | Monoclonal antibodies, immunology, inflammatory diseases |
| GSK plc | London, England, United Kingdom | Immunology, respiratory medicine, biologics, specialty pharmaceuticals |
| Biogen Inc. | Cambridge, Massachusetts, USA | Neuroimmunology, autoimmune diseases, biologic therapies |
| Boehringer Ingelheim | Ingelheim am Rhein, Germany | Immunology, respiratory diseases, inflammatory disorders |
| CSL Limited | Melbourne, Australia | Immunoglobulin therapies, immune deficiencies, plasma-derived medicines |
| Takeda Pharmaceutical Company Limited | Tokyo, Japan | Gastroenterology, immunology, rare diseases, biologics |
| LEO Pharma | Ballerup, Denmark | Medical dermatology, inflammatory skin diseases, immunology |
| Zydus Lifesciences Limited | Ahmedabad, India | Biosimilars, immunology therapeutics, specialty pharmaceuticals |
Frequently Asked Questions:
1] Which segments are covered in Immunology Drug Market report?
Ans. The segments covered in Immunology Drug Market report are based on Disease By Drug Class and By Disease Condition.
2] Which region is expected to hold the highest share in the Immunology Drug Market?
Ans. North America is expected to hold the highest share in the Vision Screeners Market.
3] What is the market size of Immunology Drug Market by 2034?
Ans. The market size of Immunology Drug Market by 2034 is USD 255.07 Bn.
4] Who are the top key players in the Immunology Drug Market?
Ans. Active Biotech, Eli Lilly and Company, Autoimmune Inc, Pfizer, GlaxoSmithKline plc, Seattle Genetics, Genentech, F. Hoffmann-La Roche Ltd., Eisai Co., Bayer AG, Sanofi Aventis LLC.
5] What was the Global Immunology Drug Market size in 2025?
Ans: The Global Immunology Drug Market size was USD 126.54 Billion in 2025.